Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination

摘要: C IRRHOSIS caused by hepatitis virus (HCV) accounts for at least 30% of all liver transplants (OLT) currently performed in adults.’ Good survival patients with such an indication has been described, even though the reappearance viral genome (HCV-RNA) occurs more than 90% during first year after transplantation.‘.’ The course recurrent HCV graft infection is generally benign. Nevertheless, some concerns about long-term outcome disease have arisen since 50% HCV-RNA positive develop chronic within two years’,2 and 35% livers are seriuosly injured (chronic active cirrhosis) 5 years transplantation.4 In present study, a therapeutic attempt to prevent was undertaken group transplant recipients, using combination interferon ribavirin early OLT. preliminary results this pilot experience, its kind, reported herein.